Allergan plc Ordinary Shares (NYSE:AGN) disclosed Monday that the FDA has granted approval for marketing its JUVEDERM VOLLURE XC meant for correction of moderate to several facial wrinkles and folds. This included nasolabial folds in adults aged above 21. The company indicated that 59 percent of subjects saw improvement in the United States pivotal clinical study.
Allergan revealed that the approval from the regulator illustrated its urgency to develop next-generation HA fillers meant to meet different needs of patients. The drug is formulated with the company’s proprietary VYCROSS technology that blends different molecular weights of hyaluronic acid that contributed to the gel’s duration.
The drug maker indicated that JUVEDERM VOLLURE XC would be available next month to physicians. The drug is specifically meant with a balance of gel firmness, as well as, low cohesivity.
The company’s chief R&D officer, David Nicholson, commented, “The FDA approval of JUVÉDERM VOLLURE™ XC demonstrates Allergan’s imperative to develop next-generation HA fillers designed to meet different patient needs. This commitment to ongoing scientific research and development is one of the factors that make JUVÉDERM®, the number one selling collection of dermal filler products.”